X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Sage Group will assist Cadrenal in exploring strategic partnerships, co-development and licensing agreements for ATI-5923 (tecarfarin), a late-stage, novel, oral and reversible anticoagulant designed to prevent heart attacks, strokes and deaths.
Lead Product(s): Tecarfarin,Warfarin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ATI-5923
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Sage Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 12, 2023
Details:
Tecarfarin is an vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin, which is investigated for the treatment of patients with antiphospholipid syndrome (APS) who require chronic anticoagulation.
Lead Product(s): Tecarfarin
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Tecarfarin is an vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin, which is investigated for the treatment of implanted medical devices for heart diseases.
Lead Product(s): Tecarfarin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
The Company intends to use the net proceeds in developing tecarfarin, a novel cardiorenal therapy for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Lead Product(s): Tecarfarin
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Details:
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib.
Lead Product(s): Tecarfarin
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
The net proceeds will be used for developing tecarfarin, a novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation.
Lead Product(s): Tecarfarin
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
